Trials / Conditions / Primary Breast Cancer

Primary Breast Cancer

20 registered clinical trials studyying Primary Breast Cancer — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Large Language Model-Based Emotional Management for Breast Cancer Patients NCT07452055	Nanfang Hospital, Southern Medical University	N/A
Enrolling By Invitation	Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 NCT07292571	Tomsk National Research Medical Center of the Russian Academy of Sciences	Phase 2
Enrolling By Invitation	[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expr NCT07275463	Tomsk National Research Medical Center of the Russian Academy of Sciences	Phase 2
Active Not Recruiting	ADIE-BC - Aligning Dimensions of Interoceptive Experience in Breast Cancer Survivors NCT06954532	King's College London	N/A
Completed	Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 NCT05923177	Tomsk National Research Medical Center of the Russian Academy of Sciences	Phase 1
Unknown	mULM to Support Breast Cancer Diagnosis and Therapy NCT05445050	RWTH Aachen University	N/A
Completed	Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy NCT04468113	Kliniken Essen-Mitte	—
Completed	Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 NCT04277338	Tomsk National Research Medical Center of the Russian Academy of Sciences	Phase 1
Unknown	Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) NCT03711877	Tao OUYANG	Phase 3
Unknown	Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative NCT03270007	Tao OUYANG	Phase 4
Completed	Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple NCT01779479	GBG Forschungs GmbH	Phase 2
Recruiting	Breast Cancer Proteomics and Molecular Heterogeneity NCT01840293	Cancer Trials Ireland	—
Unknown	Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemo NCT01019616	Tao OUYANG	Phase 3
Completed	Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Fo NCT04127019	Fudan University	Phase 3
Completed	Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Ad NCT01314833	Fudan University	Phase 3
Completed	Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care NCT01033162	University of Wisconsin, Madison	N/A
Completed	Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer NCT01049425	West German Study Group	Phase 3
Completed	Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel NCT00527449	Klinikum Weissenfels	Phase 2
Terminated	Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow NCT00172068	Novartis Pharmaceuticals	Phase 2
Completed	Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Doce NCT00793377	GBG Forschungs GmbH	Phase 3